Mutation and loss of MED12 have been reported in several types of cancer; it has been suggested that inactivation of Med12 may promote cancer through the dysregulation of several signalling pathways, including TGF-beta, mitogen-activated protein kinase kinase (MEK), extracellular-regulated protein kinases, and hormone receptors. The gene discussed is MAP2K7; the disease is cancer.